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Abstract
Background: To optimize antimicrobial dosing in different animal species, pharmacokinetic information is
necessary. Due to the plethora of cephalosporin antimicrobials and animal species in which they are used,
assessment of pharmacokinetics in all species is unfeasible. In this study we aimed to describe pharmacokinetic
data of cephalosporins by reviewing the available literature for food producing and companion animal species. We
assessed the accuracy of interspecies extrapolation using allometric scaling techniques to determine
pharmacokinetic characteristics of cephalosporins in animal species for which literature data is unavailable. We
assessed the accuracy of allometric scaling by comparing the predicted and the published pharmacokinetic value in
an animal species/humans not included in the allometric modelling.
Results: In general, excretion of cephalosporins takes place mainly through renal mechanisms in the unchanged
form and volume of distribution is limited in all animal species. Differences in plasma protein binding capacity and
elimination half-life are observed but available information was limited. Using allometric scaling, correlations
between body weight (BW) and volume of distribution (Vd) and clearance (Cl) were R2 > 0.97 and R2 > 0.95
respectively for ceftazidime, ceftiofur, cefquinome and cefepime but not ceftriaxone. The allometric exponent
ranged from 0.80 to 1.31 for Vd and 0.83 to 1.24 for Cl. Correlations on half-life ranged from R2 0.07–0.655
(literature) and R2 0.102–0.876 (calculated).
Conclusions: Allometric scaling can be applied for interspecies extrapolation of cephalosporin pharmacokinetic
parameters Vd and Cl, but not elimination half-life. We hypothesize that the accuracy could be improved by using
more refined scaling techniques.
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Background
Antimicrobials are used in both food-producing animals
like cattle, pigs, poultry and rabbits and companion
animals such as dogs, cats and horses. These animals are
known to be potential reservoirs of microorganisms
carrying antimicrobial resistance genes [1–5]. Emergence
of resistance to antimicrobials in pathogens such as
Enterobacteriaceae, Staphylococcus spp. and Streptococcus
spp. has led to an increased awareness of the need to
optimize dosing regimens [6, 7]. Third and fourth
generation cephalosporins mainly target Gram-negative
microorganisms such as Enterobacteriaceae (including
Escherichia coli) and have decreased activity against
Gram-positive microorganisms such as Staphylococcus
spp. and Streptococcus spp., the primary target of earlier
generation cephalosporins. However, before dosage regi-
mens can be optimized detailed knowledge of the pharma-
cokinetics of cephalosporins is needed. We hypothesize
that these data are available for major food-producing ani-
mal species such as cattle and pigs, but less so for species
like rabbits and companion animals.
The objective of this study is to gain accurate pharma-
cokinetic data of cephalosporins in animal species for
which these data are not available from literature. We
intend to calculate these missing pharmacokinetic data
by interspecies extrapolation of known pharmacokinetic
data in other animal species using allometric scaling.
The allometric scaling technique is one of the tech-
niques used to determine the first-in-human dose of
new drugs for clinical trials, which is also extrapolation
of pharmacokinetic data between animal species [8, 9].
Studies have already proven allometric scaling can be ap-
plied for extrapolation of pharmacokinetic data of ceph-
alosporins, but these studies were based on data from a
limited selection of animal species [10, 11]. In this study
we collect available pharmacokinetic data on cephalo-
sporins of a range of food-producing (cattle, pigs, chick-
ens, rabbits, horses) and companion animal (dogs, cats,
rabbits, horses) species and assess the accuracy of
interspecies extrapolation by allometric scaling of phar-
macokinetic data over this broad range of animal spe-
cies. We have opted for allometric scaling because this
technique is less time consuming and requires less input
parameters than more refined methods for interspecies
extrapolation, like physiologically based pharmacokinetic
(PBPK) modelling [12–14]. Also, allometric scaling is a
more widely applied and understood technique.
In this study we present and review the pharmaco-
kinetic data of cephalosporins available from litera-
ture for a wide range of animal species. Furthermore
we subject basic pharmacokinetic parameters (clear-
ance (Cl), volume of distribution (Vd) and elimin-
ation half-life (t½)) to allometric analysis and assess
the accuracy of this method based on a larger subset
of animal species than what is usually applied in
allometric analysis.
Methods
Data collection
A search for literature reporting pharmacokinetic data of
cephalosporins authorized for veterinary use and of
cephalosporins authorized for human use and which are
known to be used off-label in companion animals was
performed in PubMed, Scopus and Google Scholar.
Search statements included combinations of the follow-
ing terms: pharmacokinetics, veterinary, cephalosporins
and names of several specific animal species and/or
cephalosporins. No language restriction was applied in
the search. References describing pharmacokinetics of
combination therapies were excluded from the results as
other compounds can potentially interfere with the
pharmacokinetics of the cephalosporin(s) studied. Data
retrieved after administration by other routes than the
intravenous route was excluded in order to eliminate the
influence of absorption pharmacokinetics. Studies in that
were performed with experimental (non-therapeutic)
dosages were also excluded.
Allometric analysis
Allometric scaling based on body weight was applied to
the collected pharmacokinetic data, to the parameters
Vd, Cl and t½. These pharmacokinetic parameters are
the core parameters reported in pharmacokinetic studies
and therefore for these parameters most data is available.
Data on other pharmacokinetic indices is limited, mak-
ing allometric analysis unfeasible. The availability of data
and importance in the description of pharmacokinetic
behaviour of a compound makes Vd, Cl and t½ the best
candidates for allometric scaling.
For the analysis the allometric equation (Eq. 1) was
used, which can be written as follows [8, 9, 11, 15]:
Y ¼ aWb ð1Þ
where Y is the pharmacokinetic parameter of interest, W
is the body weight in kg, a is the coefficient of the allo-
metric equation and b is the allometric exponent. Log-
transformed this equation turns into a linear function
and the equation (Eq. 2) is represented as follows [8, 11]:
logY ¼ logaþ b logW ð2Þ
with log a being the intercept and b being the slope. As
Y and W were known parameters, values for a and b
could be calculated with a trend line. The trend line
also enabled assessment of the correlation between
pharmacokinetic values for different animal species.
Allometric scaling was performed for those active
substances with pharmacokinetic data obtained after
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intravenous administration available for at least four
different species of animals to allow for robust allomet-
ric analysis. Young animals were considered an extra
animal species due to often substantial differences in
body weight and potential differences in pharmacokin-
etics compared to adults. The mean body weight and
values for Vd, Cl and t½ were all retrieved from the col-
lected pharmacokinetic studies and no other sources
were used.
To evaluate the accuracy of extrapolation of pharma-
cokinetics across animal species with allometric models,
pharmacokinetic parameters in humans and other ani-
mal species were extrapolated (based on the reported
mean animal body weight) and then compared with the
observed pharmacokinetic parameters for the species.
Ceftazidime, authorized for human use, was evaluated
with and without human pharmacokinetic data. Ceftio-
fur and cefquinome pharmacokinetic data from other
animal species were used as reference due to the exclu-
sively veterinary use of these cephalosporins.
Analyses were performed using RStudio Version
0.98.490. 2013 (RStudio inc. Boston, USA) and Excel 2010
(Microsoft, Redmond, Washington, USA).
Results
Pharmacokinetics of cephalosporins
The collected pharmacokinetic data on cephalosporins
are presented in Additional file 1: Table S1. Pharmaco-
kinetics of 1st and 2nd generation cephalosporins for
the included animal species were available from 15 stud-
ies (horses n = 7, dogs n = 4, cats n = 2 and cattle n = 2)
involving 5 different cephalosporins (cefadroxil, cefazo-
lin, cefapirin, cefalexin and cefoxitin). An interspecies
difference was observed for plasma protein binding be-
tween horses and cattle for cefazolin (75 % in cattle,
compared to 8.3 % in horses). Comparing different ceph-
alosporins over all species, cefazolin had the shortest
elimination half-life (ranging from 0.62 h in cattle to
1.23 h in dogs) and cefalexin the longest (1.38 h in dogs
to 2.02 h in horses). Volume of distribution was limited
for all cephalosporins (ranging from 0.135 L/kg (cefazolin
in horses) to 0.374 L/kg (cefadroxil in horses)). Clearance
ranged from 0.140 L/kg/h (cefalexin and cefoxitin in cats)
to 0.598 L/kg/h (cefapirin in horses). Data was too limited
for comparison of different cephalosporins within each
animal species, except in horses. No substantial differ-
ences exist between pharmacokinetics of different cepha-
losporins in horses; t½ is short (ranging from 0.63 to
2.02 h), volume of distribution is limited (0.135–0.374 L/
kg) and excretion is mainly through renal mechanisms for
all compounds with a clearance of 0.204–0.598 L/kg/h.
For 3rd and 4th generation cephalosporins 38 studies
(cattle n = 9, chickens n = 2, pigs n = 3, horses n = 10, dogs
n = 9, cats n = 4 and rabbits n = 4) met the inclusion
criteria. Some studies covered multiple animal species.
Clinically relevant interspecies differences in elimination
half-life were observed for ceftiofur, half-life ranged from
4.23 h in chicken to 21.5 h in horses. Intermediate half-
lives were found for calves (16.1 h), pigs (11.01 h) and foals
(5.17–8.08 h). In general, elimination half-life was short for
the other cephalosporins (except cefovecin) with limited in-
terspecies differences: cefoperazone 0.50–2.13 h, ceftazi-
dime 0.73–2.31 h, ceftriaxone 0.81–3.25 h, cefotaxime
0.60–3.48 h, cefquinome 0.85–2.77 h, cefepime 1.09–2.38 h
and cefpirome 0.79–1.48 h.
Excretion of 3rd and 4th generation cephalosporins is
mainly renal and unchanged. Two 3rd and 4th gener-
ation cephalosporins are not excreted unchanged. These
are ceftiofur, which is metabolized by the liver to active
desfuroylceftiofur and cefotaxime which is metabolized
to active desacetylcefotaxime (see Additional file 1:
Table S1). Depending on the cephalosporin, elimination
can be through glomerular filtration with or without the
addition of tubular secretion. For ceftazidime it was re-
ported for cats [16] that glomerular filtration is the mech-
anism of excretion. This is confirmed by comparing the
clearance for ceftazidime in cats (0.190 L/kg/h) to the
glomerular filtration rate (GFR) measured in cats (renal
inulin clearance) of 0.182 L/kg/h) [17]. For ceftriaxone it
is reported that the mechanism of excretion in cats is
through glomerular filtration and tubular secretion and/or
non-renal excretion with a clearance of 0.370 L/kg/h [18],
which exceeds the GFR in cats. In dogs the measured GFR
(renal inulin clearance) is 0.235 L/kg/h [17]. The clearance
of ceftazidime in dogs is reported to be 0.192 L/kg/h [19]
and 0.228 L/kg/h [20]. This relates very well to the GFR in
dogs. The reported clearance of ceftriaxone is 0.217 L/kg/
h [21] in dogs, which is also close to the GFR. This might
indicate that ceftazidime is excreted exclusively through
glomerular filtration in both dogs and cats, yet, for ceftri-
axone this only seems to be the case for dogs and not for
cats. The renal clearance of cefquinome ranges from 0.191
to 0.221 L/kg/h [22] in dogs. Although the mechanism of
excretion is not mentioned in the study, it correlates so
well to the GFR in dogs that also cefquinome is probably
excreted exclusively through glomerular filtration in dogs.
Data on cats is not available.
Allometric analysis
Sufficient pharmacokinetic data to apply allometric ana-
lysis was available for five cephalosporins, cefquinome,
ceftriaxone, ceftazidime, ceftiofur and cefepime. The re-
sults of the allometric scaling regression analysis (allomet-
ric coefficient, allometric exponent and correlation (R2))
of volume of distribution, clearance and elimination half-
life are shown in Table 1. Graphs on the allometric scaling
of ceftazidime (including human data) and cefquinome
(exclusively veterinary use) are presented in Fig. 1. The
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allometric analyses of cefepime, ceftriaxone and ceftiofur
are shown in Additional file 1: Figure S1 t/m S3.
Additional file 1: Figure S4 shows the allometric analysis
for ceftazidime excluding human data. For ceftazidime,
ceftiofur, cefquinome and cefepime (but not ceftriaxone)
correlations between body weight and both parameters
volume of distribution and clearance were high (R2 > 0.97
and R2 > 0.95 respectively). The allometric exponent for all
five cephalosporins ranged from 0.80 to 1.31 for Vd and
0.83 to 1.24 for Cl. Half-life proved to be less predictable
using allometric scaling with R2 0.067–0.655 based on the
values for half-life retrieved from literature. Calculating
half-life (t½ = (ln2*Vd)/Cl) improved correlation to a
range of R2 0.102–0.876. The calculated half-life per
study is available in Additional file 1: Table S1. For
cefepime correlation improved the most after calculat-
ing (from R2 0.628 to 0.876). Correlations for ceftriax-
one and ceftazidime remained almost equal (R2 0.067
versus 0.102 and R2 0.655 versus 0.662 respectively)
and dropped for ceftiofur and cefquinome (R2 0.481
versus 0.128 for ceftiofur and R2 0.388 versus 0.243
for cefquinome).
To further assess accuracy of extrapolation of pharma-
cokinetics to humans for ceftriaxone, ceftazidime and
cefepime, two human pharmacokinetic studies per ceph-
alosporin were used to compare extrapolated pharmaco-
kinetics to observed data. For ceftazidime allometric
scaling was repeated with the human data included, to
assess the changes to the allometric equation and correl-
ation coefficient. The scaling including human data is
shown in Fig. 1 (without human data in Additional
file 1: Figure S4). As can be seen in the figures and
Table 1 the correlation drops for all three pharmaco-
kinetic parameters, especially for the elimination half-
life (from R2 0.655 to 0.472). For ceftriaxone and ce-
fepime no allometric scaling including human data
was performed. All studies were performed on healthy
volunteers, as pharmacokinetics used for the allomet-
ric model were also mostly assessed in healthy ani-
mals. For ceftiofur three additional animal species
were used with a wide range of body weights, namely
goats, camels and Asian elephants. For cefquinome
studies in ducks and buffalo were used. Data and re-
sults are presented in Table 2. Pharmacokinetics for
cefepime could be extrapolated to humans with the
animal based allometric equation. For ceftazidime the
model overestimated the pharmacokinetic values. Ob-
served Vd was 30–40 % lower than the predicted
value and observed Cl was 35–40 % lower than pre-
dicted. For ceftriaxone the model overestimated the
observed value for Vd about 4 times (extrapolated
0.4 L/kg, observed 0.1 L/kg) and the value for Cl
about 23 times (extrapolated 0.280 L/kg/h, observed
0.012 L/kg/h). Allometric scaling of ceftiofur was only
Table 1 Allometric scaling of pharmacokinetics of different cephalosporins in animals
Cephalosporin Included animal
species
Total no. of
animals included (n)
Pharmacokinetic
parameter
Allometric
coefficient
Allometric
exponent
R2 (R2 including
human data)
R2 with
calculated t½
References
Ceftriaxone Dogs, cats, foals,
horses
22 Half-life 1.9820 0.0896 0.0672 0.102 [18, 21, 31, 32]
Volume of
distribution
0.9213 0.8044 0.7173
Clearance 0.4569 0.8854 0.9158
Ceftazidime Dogs (puppies
and adults), cats,
cattle, rabbits
34 Half-life 0.7690 0.0768 0.6550 (0.4719) 0.662 Animal + human
data [16, 19, 20,
33–35]:Volume of
distribution
0.2670 1.0611 0.9829 (0.9773)
Clearance 0.3158 0.8306 0.9787 (0.9683)
Ceftiofur Calves, chickens,
foals, horses
68 Half-life 3.7440 0.2155 0.4811 0.128 [36–41]
Volume of
distribution
0.1485 1.3129 0.9875
Clearance 0.0210 1.2431 0.9552
Cefquinome Dogs, calves,
piglets, chickens,
horses, rabbits
51 Half-life 0.8230 0.1389 0.3878 0.243 [22, 42–45]
Volume of
distribution
0.2604 0.9551 0.9854
Clearance 0.3032 0.8524 0.9790
Cefepime Dogs, calves,
foals, horses
29 Half-life 0.7337 0.1787 0.6284 0.876 [46–49]
Volume of
distribution
0.1174 1.1347 0.9783
Clearance 0.1827 0.8439 0.9725
For details on pharmacokinetic data, see Additional file 1: Table S1. In the presented results both young and adult animals were included in the allometric analysis. The
values reported here are excluding any human data, except for ceftazidime, where allometric analysis was performed both with and without human data
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accurate for clearance in goats. Pharmacokinetic
values for cefquinome could be extrapolated to ducks
with reasonable accuracy, but the clearance in buffalo
was overestimated (extrapolated 0.149 L/kg/h, ob-
served 0.061 L/kg/h).
Discussion
Pharmacokinetic data on cephalosporins in different ani-
mal species presented here shows that, independent of
animal species, cephalosporins have a limited distribution
in body tissues other than plasma, undergo no or little
Fig. 1 Two examples of allometric analysis performed on pharmacokinetic data of cephalosporins. Figure shows clearance, volume of distirubution and
half-life of ceftazidime (3rd generation cephalosporin) and cefquinome (4th generation cephalosporin). Ceftazidime is also used in human medicine,
human data are included in this figure and the equation and R2 shown are based on allometric analysis including human data
Table 2 Extrapolated volume of distribution and clearance by allometric scaling versus volume of distribution and clearance
Cephalosporin (Animal)
species
Reported body
weight (kg)
Extrapolated volume
of distribution (L/kg)
Extrapolated
clearance (L/kg/h)
Observed volume of
distribution (L/kg)
Observed
clearance (L/kg/h)
Reference
Ceftriaxone Human 72 0.40 0.28 0.11 ± 0.02 0.012 a Paradis [34]
Human 79 0.39 0.28 0.12 ± 0.02 0.011 c Chiu [50]
Ceftazidime Human 72.0 0.35 0.15 0.21 ± 0.03 0.095 ± 0.014 a Paradis [34]
Human 70.8 0.35 0.15 0.204 ± 0.02 0.069 ± 0.011e Paulfeuerborn
[35]
Cefepime Human 70 0.21 0.09 0.23 0.092 b Bacher [51]
Human 74 0.21 0.09 0.25 0.101 b Barbhaiya [52]
Ceftiofur Goat
(non-lactating)
58.5 0.53 0.06 0.25 0.067 a Courtin [53]
Camel 400 0.97 0.09 0.13 ± 0.03 0.03 ± 0.001 Goudah [54]
Asian
elephant
3530 1.91 0.15 0.51 ± 0.29 0.069 ± 0.043 Dumonceaux
[55]
Cefquinome Duck 2.2 0.25 0.27 0.41 ± 0.04 0.22 ± 0.02 Yuan [56]
Buffalo 123 0.21 0.15 0.26 ± 0.006 0.061 d Dinakaran [57]
Data are observed values from pharmacokinetic studies after intravenous administration of cephalosporin to healthy subjects. Values are reported as value ± SD
where possible
a Recalculated from ml/kg/min. b Recalculated from ml/min. c Recalculated from L/h. d Recalculated from ml/kg/h. e Recalculated from ml/min/1.73 m2 (assuming
1.73 m2 equals a 70 kg weighing human)
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biotransformation and the primary route of elimination is
through renal mechanisms with a generally short elimin-
ation half-life. Our study underlines the possibility of in-
terspecies extrapolation of pharmacokinetic parameters of
cephalosporins with allometric scaling, at least for volume
of distribution and clearance and less for elimination half-
life. In other studies, allometric scaling of a variety of
drugs (not cephalosporins) also showed good overall cor-
relation of volume of distribution and clearance with body
weight across species, especially when at least one large
animal (for example cattle or horses) were added to the
scaling besides laboratory animals such as mice, rats and
dogs [8]. Only one of the four cephalosporins used in allo-
metric analyses by Riviere et al. [11] showed a high correl-
ation between body weight and elimination half-life (R2 of
0.97 for cefapirin). For the other three cephalosporins cor-
relation was poor (R2 0.03 for cefamandole, 0.07 for cefa-
zolin and 0.20 for cefalothin). These findings are in
agreement with the results presented in this paper. It
should be noted, however, that for some drugs elimination
half-life does scale well with body weight, as shown with
carboplatin in several avian species [23] and for example
tetracycline (R2 0.97) by Riviere et al. [11] and should
therefore still be considered as a scaling parameter when
performing allometric analysis.
Although the pharmacokinetic profile of cephalo-
sporins in general was comparable between animal
species some specific differences were noted. One of
the observed differences was in the plasma protein
binding. Values for plasma protein binding were only
scarcely reported in the reviewed studies and there-
fore impossible to extrapolate to other animal species.
Results in laboratory animals showed high protein
binding for ceftriaxone in rabbits and rodents [24]
and an overall higher plasma protein binding in rab-
bits compared to rodents and dogs, independent of
cephalosporin [25]. The effect of plasma protein bind-
ing on pharmacokinetics can be substantial for drugs
with high protein binding and renal clearance, as is
reported for cefovecin. High plasma protein binding
is thought to account for the extremely long elimin-
ation half-life of cefovecin in cats and dogs [26, 27].
but in order to understand the exact impact of
plasma protein binding on pharmacokinetics of ceph-
alosporins more experimental data is needed.
Also, some cephalosporins like ceftriaxone, are elimi-
nated through the faeces as well as through urine, but
not to the same extent in all animal species. Pharma-
cokinetics of drugs that are primarily excreted biliary
prove harder to extrapolate due to differences in bil-
iary excretion and bile flow rates between animal spe-
cies. Dogs and chickens are good biliary excretors,
while cats are moderate and rabbits and humans are
poor biliary excretors [28]. Furthermore, interspecies
differences in enterohepatic circulation and urine pH
exist that can influence elimination pharmacokinetics
[11]. Carnivores such as dogs and cats generally have
acidic urine (pH 5.5–7.0) while herbivores like cattle
and horses have alkaline urine (pH 7.0–9.0) [28]. Ex-
trapolation can also be expected to be less accurate for ac-
tive compounds undergoing capacity-limited hepatic
biotransformation rather than flow limited hepatic bio-
transformation and excretion as interspecies differences
exist for these drug metabolism processes. This may con-
tribute to the differences in metabolism of ceftiofur, which
probably leads to the poor extrapolation of pharmacokin-
etics across animal species observed here. Cats, for ex-
ample, are known to be poor in glucuronidation while
dogs on the other hand are deficient acetylators and pigs
lack sulfation capacity [28]. Cattle is known to metabolize
ceftiofur very efficiently to desfuroylceftiofur [29], perhaps
to a greater extent than other animal species. It should
also be noted that the young age of the calves could have
influenced the results, as young animals have relatively
more water and less fat than adult animals (influencing
volume of distribution) and organs involved in drug me-
tabolism and elimination still mature in the first few
months of life [28].
Finally, it could be hypothesized that coprophagy
(or caecotrophy) increases gut exposure to antimicro-
bials and alters pharmacokinetics of active substances
in animals that display this behaviour (such as rab-
bits, who eat the soft parts of their own excrement,
but also pigs, horses and dogs who eat the excre-
ments from other animals [30]). However, no litera-
ture is available to assess the significance on these
processes and in our results we observed no particu-
lar differences in pharmacokinetics in rabbits com-
pared to other animal species.
Allometric scaling of the pharmacokinetics of cephalo-
sporins will assist the parametrization of models for
simulation of drug distribution in food-producing and
companion animals, such as PBPK models. Where allo-
metric scaling is applied for extrapolation of pharmaco-
kinetic values, PBPK models can extrapolate plasma and
tissue concentration-time curves of chemical com-
pounds across animal species, which is ideal for dose
optimization of antimicrobials for different animal
species.
Conclusion
Pharmacokinetic behaviour of cephalosporin antimicro-
bials is in general very similar between animal species.
It was shown that extrapolation of pharmacokinetic
values for volume of distribution and clearance of most
cephalosporins across food-producing and companion
animal species can be performed using allometric
scaling.
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Additional file
Additional file 1: Pharmacokinetics of cephalosporins in food
producing and companion animal species obtained from literature and
presented in a table with literature references. We also provide additional
graphs displaying the allometric analysis of cefepime, ceftriaxone,
ceftiofur and ceftazidime. (PDF 666 kb)
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